InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research note released on Friday morning. The firm issued a sell rating on the stock.

Separately, Lake Street Capital initiated coverage on shares of InspireMD in a research report on Wednesday, December 11th. They set a “buy” rating and a $5.00 target price on the stock.

InspireMD Price Performance

NSPR stock opened at $2.94 on Friday. The company’s 50 day simple moving average is $2.79 and its 200-day simple moving average is $2.73. The firm has a market capitalization of $76.68 million, a PE ratio of -3.92 and a beta of 1.00. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.42.

Hedge Funds Weigh In On InspireMD

Large investors have recently bought and sold shares of the stock. Schonfeld Strategic Advisors LLC raised its stake in shares of InspireMD by 153.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock valued at $79,000 after acquiring an additional 18,233 shares during the period. Northern Trust Corp raised its stake in shares of InspireMD by 103.7% in the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock valued at $126,000 after acquiring an additional 24,452 shares during the period. Renaissance Technologies LLC purchased a new position in shares of InspireMD in the 4th quarter valued at $27,000. Essex Investment Management Co. LLC purchased a new position in shares of InspireMD in the 4th quarter valued at $191,000. Finally, Legato Capital Management LLC purchased a new position in shares of InspireMD in the 4th quarter valued at $47,000. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.